A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE
Lymphoma Research/Clinical Trials Bookmark and Share

Lymphoma Research and Care: New Treatments Start With Clinical Trials

The Toni Stephenson Lymphoma Center at City of Hope has long been a leader in lymphoma research. Our research projects have been funded by the National Cancer Institute (NCI) and many other research-based organizations, and our scientists collaborate with other leading research institutions to develop tomorrow’s breakthroughs today.
 
With our extensive program of lymphoma clinical trials, City of Hope can provide our patients access to novel therapies, including many that are not available elsewhere.
 
and  Christine Brown, Ph.D., associate director of the T-cell Immunotherapy Laboratory, have opened an Food and Drug Administration (FDA )- approved clinical trial of an investigational drug for patients with T-cell lymphoma who are undergoing transplantation for recurrent disease, to reduce the chance of relapse. Plans are now underway to extend this promising new therapy to treat patients with B-cell lymphoma who are not undergoing transplantation. That trial is expected to begin this year.
 
Amrita Y. Krishnan, M.D., director, Multiple Myeloma Program, is leading an international clinical trial to test whether Zevalin radioimmunotherapy given prior to high-dose chemotherapy plus autologous stem cell transplantation will reduce the rate of disease recurrence and improve overall and disease-free survival in patients with aggressive lymphoma. City of Hope was the first institution to show that hematopoietic stem cell transplantation could cure patients of lymphoma who suffered from HIV infection. This has changed the standard of care for patients in the U.S. Joseph Alvarnas, M.D., associate clinical professor of hematology and hematopoietic cell transplantation is leading a national trial in the treatment of patients with lymphoma and HIV infection. He is also leading a study aimed at determining whether allogeneic (donor) transplants will cure both leukemia and HIV infection.
 
Leslie Popplewell, M.D., associate clinical professor , and Robert Chen, M.D., assistant professor, both of the Department of Hematology & Hematopoietic Cell Transplantation, continue to advance clinical trials of new agents that may be more effective and less toxic in treating patients with hematologic cancers. Chen led a national study of the drug brentuximab in patients with relapsed Hodgkin disease, in whom the drug produced a high rate of response. The drug was subsequently approved by the FDA. Current research is directed at assessing the efficacy of brentuximab in preparing patients for transplant, as well as in preventing posttransplant relapse.
 
 

Lymphoma Research/Clinical Trials

Lymphoma Research and Care: New Treatments Start With Clinical Trials

The Toni Stephenson Lymphoma Center at City of Hope has long been a leader in lymphoma research. Our research projects have been funded by the National Cancer Institute (NCI) and many other research-based organizations, and our scientists collaborate with other leading research institutions to develop tomorrow’s breakthroughs today.
 
With our extensive program of lymphoma clinical trials, City of Hope can provide our patients access to novel therapies, including many that are not available elsewhere.
 
and  Christine Brown, Ph.D., associate director of the T-cell Immunotherapy Laboratory, have opened an Food and Drug Administration (FDA )- approved clinical trial of an investigational drug for patients with T-cell lymphoma who are undergoing transplantation for recurrent disease, to reduce the chance of relapse. Plans are now underway to extend this promising new therapy to treat patients with B-cell lymphoma who are not undergoing transplantation. That trial is expected to begin this year.
 
Amrita Y. Krishnan, M.D., director, Multiple Myeloma Program, is leading an international clinical trial to test whether Zevalin radioimmunotherapy given prior to high-dose chemotherapy plus autologous stem cell transplantation will reduce the rate of disease recurrence and improve overall and disease-free survival in patients with aggressive lymphoma. City of Hope was the first institution to show that hematopoietic stem cell transplantation could cure patients of lymphoma who suffered from HIV infection. This has changed the standard of care for patients in the U.S. Joseph Alvarnas, M.D., associate clinical professor of hematology and hematopoietic cell transplantation is leading a national trial in the treatment of patients with lymphoma and HIV infection. He is also leading a study aimed at determining whether allogeneic (donor) transplants will cure both leukemia and HIV infection.
 
Leslie Popplewell, M.D., associate clinical professor , and Robert Chen, M.D., assistant professor, both of the Department of Hematology & Hematopoietic Cell Transplantation, continue to advance clinical trials of new agents that may be more effective and less toxic in treating patients with hematologic cancers. Chen led a national study of the drug brentuximab in patients with relapsed Hodgkin disease, in whom the drug produced a high rate of response. The drug was subsequently approved by the FDA. Current research is directed at assessing the efficacy of brentuximab in preparing patients for transplant, as well as in preventing posttransplant relapse.
 
 
Quick Links
A $10 million gift from Internet-publishing entrepreneurs Emmet and Toni Stephenson and their daughter Tessa Stephenson Brand will fund the creation of the Toni Stephenson Lymphoma Center at City of Hope, the cornerstone of the institution’s new Hematologic Cancers Institute.
Hematologic Cancers Support Groups
Low-dose Tamoxifen for Radiation-Induced Breast Cancer Risk Reduction Trial
 
A clinical research study is currently underway to see if low-dose tamoxifen can reduce the risk of breast cancer in childhood, adolescent, and young adulthood cancer survivors.


NEWS & UPDATES
  • We’ve seen it in science fiction: The aliens begin terra-forming a planet to create a friendly habitat that gives them, not the inhabitants, all the advantages when the colonization begins. Turns out, cancer does essentially the same thing when it metastasizes, according to new research from City of Hope. The f...
  • Equipping the immune system to fight cancer – a disease that thrives on mutations and circumventing the body’s natural defenses – is within reach. In fact, City of Hope researchers are testing one approach in clinical trials now. Scientists take a number of steps to turn cancer patients’ T cells – white b...
  • As treatments for lung cancer become more targeted and effective, the need for better technology to detect lung cancer mutations becomes increasingly important. A new clinical study at City of Hope is examining the feasibility of using blood and urine tests to detect lung cancer mutations, potentially allowing ...
  • When it comes to breast cancer risk, insulin levels may matter more than weight, new research has found. The study from Imperial College London School of Public Health, published in the journal Cancer Research, indicates that metabolic health – not a person’s weight or body mass index – increases breast cancer ...
  • No one ever plans to have cancer – and there’s never a good time. For Homa Sadat, her cancer came at a particularly bad time: just one year after losing her father to the pancreatic cancer he had battled for two years. She was working a grueling schedule managing three commercial office buildings. She’d just [&...
  • Patients at City of Hope – most of whom are fighting cancer – rely on more than 37,000 units of blood and platelets each year for their treatment and survival. Every one of those units comes from family, friends or someone who traded an hour or so of their time and a pint of their […]
  • Surgery is vital in the treatment of cancer – it’s used to help diagnose, treat and even prevent the disease – so a new colorectal cancer study linking a decrease in surgeries for advanced cancer to increased survival rates may raise more questions than it answers for some patients. The surgery-and-surviv...
  • Age is the single greatest risk factor overall for cancer; our chances of developing the disease rise steeply after age 50. For geriatric oncology nurse Peggy Burhenn, the meaning is clear: Cancer is primarily a geriatric condition. That’s why she is forging inroads in the care of older adults with cancer. Burh...
  • One of American’s great sportscasters, Stuart Scott, passed away from recurrent cancer of the appendix at the young age of 49. His cancer was diagnosed when he was only 40 years old. It was found during an operation for appendicitis. His courageous fight against this disease began in 2007, resumed again with an...
  • When Homa Sadat found a lump in her breast at age 27, her gynecologist told her what many doctors say to young women: You’re too young to have breast cancer. With the lump dismissed as a harmless cyst, she didn’t think about it again until she was at a restaurant six months later and felt […]
  • What most people call a “bone marrow transplant” is not actually a transplant of bone marrow; it is instead the transplantation of what’s known as hematopoietic stem cells. Such cells are often taken from bone marrow, but not always. Hematopoietic stem cells are simply immature cells that can ...
  • Doctors have long known that women with a precancerous condition called atypical hyperplasia have an elevated risk of breast cancer. Now a new study has found that the risk is more serious than previously thought. Hyperplasia itself is an overgrowth of cells; atypical hyperplasia is an overgrowth in a distorted...
  • Don’t kid yourself. Just because it’s mid-January doesn’t mean it’s too late to make resolutions for a happier, and healthier, 2015. Just consider them resolutions that are more mature than those giddy, sometimes self-deluded, Jan. 1 resolutions. To that end, we share some advice from Cary A. Presant, M.D., an ...
  • Sales and marketing executive Jim Murphy first came to City of Hope in 2002 to donate blood for a friend who was being treated for esophageal cancer. The disease is serious. Although esophageal cancer accounts for only about 1 percent of cancer diagnoses in the U.S., only about 20 percent of patients survive at...
  • Aaron Bomar and his family were celebrating his daughter’s 33rd birthday in September 2014 when he received alarming news: According to an X-ray taken earlier that day at an urgent care facility, he had a node on his aorta and was in danger of an aneurysm. Bomar held hands with his wife and daughter and s...